Pathologic T2 Stage Subgroups and Recurrence-Free Survival After Radical Prostatectomy

Urology

Volumn 72, Issue 6, 2008, Pages 1214-1218

  DeCastro, G Joel ^a   McCann, Tara ^a   Benson, Mitchell C ^a   McKiernan, James M ^a  

^a New York Presbyterian Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 56449125189     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.01.054     Document Type: Article

References (15)

1. Mackillop W.J., O'Sullivan B., and Gospodarowicz M. The role of cancer staging in evidence-based medicine. Cancer Prev Control 2 (1998) 269-277
2. Beahrs O.H., Henson D.E., Hutter R.V.P., et al. American Joint Committee on Cancer Staging Manual (1992), Lippincott, Philadelphia pp 181-186
3. Fleming I.D., Cooper J.S., Henson D.E., et al. American Joint Committee on Cancer Staging Manual (1997), Lippincott, Philadelphia pp 219-222
4. Cagiannos I., Graefen M., Karakiewicz P.I., et al. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?. J Clin Oncol 20 (2002) 2025-2030
5. Han M., Walsh P.C., Partin A.W., et al. Ability of the 1992 and 1997 American Joint Committee on cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. J Urol 164 (2000) 89-92
6. Stamey T.A., Sozen T.S., Yemoto C.M., et al. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol 159 (1998) 2009-2012
7. Greene F. American Joint Committee on Cancer Staging Manual (2002), Springer-Verlag, New York pp 308-314
8. Banerjee M., Biswas D., Sakr W., et al. Recursive partitioning for prognostic grouping of patients with clinically localized prostate carcinoma. Cancer 89 (2000) 404-411
9. Han H., Partin A.W., Zahurak A., et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523
10. Quinn D.I., Henshall S.M., Haynes A.M., et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 19 (2001) 3692-3705
11. Lau W.K., Bergstralh E.J., Blute M.L., et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 167 (2002) 117-122
12. Ung J.O., Richie J.P., Chen M.H., et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60 (2002) 458-463
13. Ramos C.G., Roehl K.A., Antenor J.V., et al. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 172 (2004) 137-140
14. Hutter R.V., Montie J.E., Busch C., et al. Current prognostic factors and their relevance to staging. Cancer 78 (1996) 369-371
15. Renshaw A.A., Richie J.P., Loughlin K.R., et al. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 85 (1998) 1208-1210